secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2026-07-30T12:06:08+00:00
Accession:  0001104659-26-088481
Event type: regulatory
Sentiment:  neutral
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune presents RP1+nivolumab data at FDA advisory committee for advanced melanoma BLA
--------------------------------------------------------------------------------

- RP1 (vusolimogene oderparepvec) + nivolumab BLA resubmission discussed at FDA advisory committee on July 30, 2026.
- IGNYTE trial ORR 33.6% (95% CI: 25.8-42), CR 16.4%, median DoR 24.8 months in anti-PD-1 failed advanced melanoma.
- Safety profile: mainly Grade 1-2, no treatment-related Grade 5 events; 7.9% discontinued RP1 due to TEAE.
- FDA clinical review initially recommended accelerated approval; committee to address response assessment and contribution of effect.
- Unmet need: only lifileucel (AMTAGVI) approved post anti-PD-1; RP1 offers single-arm data with durable responses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926088481/0001104659-26-088481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926088481/tm2621663d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-088481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer